This page is informational only, is not medical advice, and does not guarantee any specific outcome
It modulates over 4,000 genes involved in tissue remodeling, suppresses pro-inflammatory cytokines (IL-6, TNF-alpha), and activates proteasome and antioxidant pathways (Pickart et al., BioMed Res Int, 2012)
These medications have a long half-life, meaning they remain active in your system for several days, but consistent weekly doses ensure they stay at optimal levels
Bristol Myers inks pact with Molecular Templates, abandons CAR-T therapy orva-cel Earlier this month, Bristol Myers Squibb finally bagged US Food and Drug Administrations approval for its new CAR-T therapy Breyanzi (lisocabtagene maraleucel, or liso-cel) for adults with relapsed or refractory large B-cell lymphoma